NasdaqCM:VRDNBiotechs
Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings
If you are wondering whether Viridian Therapeutics at around US$16.97 is priced for opportunity or risk, the key question is what that tag really says about the business.
The stock has recently shown sharp moves, with returns of 25.9% over 7 days and 21.6% over 30 days, while year to date it is down 44.7% and up 32.8% over the past year.
This mix of recent gains and earlier weakness has put valuation back in focus as investors reassess what they are willing to pay for Viridian Therapeutics...